{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:58:56Z","timestamp":1785581936793,"version":"3.56.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Myelofibrosis (MF) is a rare and progressive blood disorder marked by fibrosis of the bone marrow, abnormal blood cell production, and often severe anemia. The disease is commonly associated with debilitating symptoms such as fatigue, weakness, and an enlarged spleen. Ojjaara (momelotinib), a selective inhibitor of Janus kinases (JAK1\/2), offers a promising treatment option for patients with MF, particularly those suffering from anemia. By targeting the dysregulated JAK-STAT signaling pathway, Ojjaara helps restore normal blood cell production and reduces fibrosis in the bone marrow. Several clinical trials, including the MOMENTUM and SIMPLIFY-1 studies, have highlighted the drug\u2019s ability to improve symptoms related to anemia, decrease spleen size, and enhance overall quality of life, with a manageable side effect profile. This review examines the role of momelotinib in treating MF, focusing on its mechanism, clinical benefits, patient selection criteria, monitoring strategies, potential side effects, and findings from key clinical trials. While promising, careful patient management is essential to minimize adverse effects and optimize the therapeutic benefits of momelotinib in MF treatment.<\/jats:p>","DOI":"10.1097\/ms9.0000000000003845","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T01:00:11Z","timestamp":1757984411000},"page":"7172-7176","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Advancements in myelofibrosis management: a comprehensive analysis of Ojjaara (Momelotinib) therapy and clinical perspectives"],"prefix":"10.1097","volume":"87","author":[{"given":"Areeba Aamir Ali","family":"Basaria","sequence":"first","affiliation":[{"name":"Internal Medicine, Dow University of Health Sciences (DUHS), Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabeea","family":"Tariq","sequence":"additional","affiliation":[{"name":"Internal Medicine, Dow University of Health Sciences (DUHS), Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areeba","family":"Ahsan","sequence":"additional","affiliation":[{"name":"Internal Medicine, Dow University of Health Sciences (DUHS), Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Ahad","family":"Ahsan","sequence":"additional","affiliation":[{"name":"Internal Medicine, Jinnah Sindh Medical University (JSMU), Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin R.","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Research and Development, Shing Huei Group, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigue Fikiri","family":"Bavurhe","sequence":"additional","affiliation":[{"name":"Department of Research, Medical Research Circle (MedReC), Goma, DR, Congo"},{"name":"Faculty of Medicine, Official University of Bukavu, Bukavu, DR, Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Peter Mulindwa","family":"Murhula","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Evangelic University in Africa, Bukavu, DR, Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jospin","family":"Bisimwa","sequence":"additional","affiliation":[{"name":"Ecole r\u00e9gionale de sant\u00e9 publique, Catholic University of Bukavu, Bukavu, DR, Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-1215","authenticated-orcid":false,"given":"Aymar","family":"Akilimali","sequence":"additional","affiliation":[{"name":"Department of Research, Medical Research Circle (MedReC), Goma, DR, Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"R1-20260801","doi-asserted-by":"crossref","first-page":"232","DOI":"10.7326\/0003-4819-74-2-232","article-title":"Acute myelofibrosis","volume":"74","author":"Bergsman","year":"1971","journal-title":"Ann Intern Med"},{"key":"R2-20260801","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","article-title":"Momelotinib: an emerging treatment for myelofibrosis patients with anemia","volume":"15","author":"Chifotides","year":"2022","journal-title":"J Hematol Oncol"},{"key":"R3-20260801","first-page":"100082","article-title":"Transparency In The reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Premier Journal of Science"},{"key":"R4-20260801","doi-asserted-by":"crossref","first-page":"660\u201371","DOI":"10.3324\/haematol.2015.141283","article-title":"Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies","volume":"101","author":"Zahr","year":"2016","journal-title":"Haematologica"},{"key":"R5-20260801","doi-asserted-by":"crossref","first-page":"3844\u201350","DOI":"10.1200\/JCO.2017.73.4418","article-title":"Journal of clinical oncology simplify-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-Na\u00a8\u0131veNa\u00a8\u0131ve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"key":"R6-20260801","doi-asserted-by":"crossref","first-page":"2559\u201371","DOI":"10.2217\/fon-2022-0276","article-title":"Momelotinib for the treatment of myelofibrosis with anemia","volume":"18","author":"Tremblay","year":"2022","journal-title":"Future Oncology"},{"key":"R7-20260801","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s13104-021-05860-w","article-title":"Interferon-\u03b3 induces interleukin-6 production by neutrophils via the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway","volume":"14","author":"Yoshida","year":"2021","journal-title":"BMC Res Notes"},{"key":"R8-20260801","doi-asserted-by":"crossref","first-page":"269\u201380","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"The Lancet"},{"key":"R9-20260801","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41408-022-00780-9","article-title":"Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS-911543 JAK2 inhibitor","volume":"13","author":"Gangat","year":"2023","journal-title":"Blood Cancer J"},{"key":"R10-20260801","first-page":"787\u201398","article-title":"Abstract","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"R12-20260801","doi-asserted-by":"crossref","first-page":"1449\u201358","DOI":"10.2217\/fon-2020-1048","article-title":"MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic","volume":"17","author":"Verstovsek","year":"2021","journal-title":"Future Oncology"},{"key":"R13-20260801","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41408-018-0067-6","article-title":"Momelotinib therapy for myelofibrosis: a 7-year follow-up","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"key":"R14-20260801","doi-asserted-by":"crossref","first-page":"94\u2013102","DOI":"10.3324\/haematol.2016.148924","article-title":"A phase 1\/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis","volume":"102","author":"Gupta","year":"2017","journal-title":"Haematologica"},{"key":"R15-20260801","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41408-021-00526-z","article-title":"Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis","volume":"11","author":"Sureau","year":"2021","journal-title":"Blood Cancer J"},{"key":"R16-20260801","doi-asserted-by":"crossref","first-page":"4282\u20134282","DOI":"10.1182\/blood-2018-99-111349","article-title":"Hepcidin suppression by momelotinib is associated with increased iron availability and erythropoiesis in transfusion-dependent myelofibrosis patients","volume":"132","author":"Oh","year":"2018","journal-title":"Blood"},{"key":"R17-20260801","doi-asserted-by":"crossref","first-page":"159\u201365","DOI":"10.1007\/s10637-018-0650-5","article-title":"Phase 1 dose-escalation study of momelotinib, a Janus kinase 1\/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma","volume":"37","author":"Ng","year":"2019","journal-title":"Invest New Drugs"},{"key":"R19-20260801","doi-asserted-by":"crossref","first-page":"1929\u201338","DOI":"10.1080\/14656566.2017.1404574","article-title":"The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium","volume":"18","author":"Griesshammer","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"R21-20260801","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/HS9.0000000000000001","article-title":"Myelofibrosis-related anemia: current and emerging therapeutic strategies","volume":"1","author":"Naymagon","year":"2017","journal-title":"Hemasphere"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000003845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:10:40Z","timestamp":1785579040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000003845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003845","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"2024-12-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}